External Beam Radiation With Intratumoral Injection of Dendritic Cells As Neo-Adjuvant Treatment for Sarcoma

Inclusion Criteria: * Intermediate or high grade sarcoma as determined by pathology review * Musculoskeletal tumor in extremities, trunk or chest wall. * Primary tumor or isolated locally recurrent tumor greater than 5 cm in diameter. * Clinical Stage T2N0M0 (AJCC 6th edition) * Patient is not a candidate for neoadjuvant chemotherapy. * Performance status Eastern Cooperative Oncology Group (ECOG) 0 or 1. * No steroid therapy within 4 weeks of first dendritic cell administration. * No coagulation disorder. * Patient's written informed consent. * No contraindication to resection. * Adequate organ function (measured within a week of beginning treatment). * White blood count (WBC) \> 3,000/mm to the third power and absolute neutrophil count (ANC) \>1500/mm to the third power * Platelets \> 100,000/mm to the third power * Hematocrit \> 25% * Bilirubin \< 2.0 mg/dL * Creatinine \< 2.0 mg/dL, or creatinine clearance \> 60 mL/min * Radiation Oncologist must confirm that a 2-3 cm strip of skin can be spared from radiation. Exclusion Criteria: * Retroperitoneal location. * Gastrointestinal stromal tumor (GIST). * Demonstrated metastatic disease. * Prior radiation therapy if the current tumor is locally recurrent after prior resection. * Concurrent treatment with any anticancer agent other than radiation as dictated by the protocol. * Bleeding disorder. * H.I.V. infection or other primary immunodeficiency disorder. * Ongoing systemic therapy with immunosuppressant drugs (e.g. corticosteroids, azathioprine, cyclosporin, methotrexate). * Any serious ongoing infection. * Pregnant or lactating women -- Patients in reproductive age must agree to use contraceptive methods for the duration of the study (a pregnancy test will be obtained before treatment). * ECOG performance status of 2, 3 or 4.